The DOI matches its Crossref record.
Inhibition of Cyclooxygenase: A Novel Approach to Cancer Prevention
Abstract
An expanding body of evidence indicates that downregulation of the cyclooxygenases (Cox-1 and Cox-2) will be an important strategy for preventing cancer because cyclooxygenases catalyze the formation of prostaglandins (PGs), and PGs have multiple effects that favor tumorigenesis. PGs also are more abundant in cancers than in the normal tissues from which cancers arise. Overexpression of Cox-2 in epithelial cells inhibits apoptosis and increases the invasiveness of tumor cells; inhibitors of Cox (e.g., NSAIDS) are chemopreventive; and tumorigenesis is inhibited in Cox-2 knockout mice. We focus in this review on strategies to selectively inhibit and downregulate the Cox-2 isoform. This is important because simultaneous inhibition of Cox-1 (constitutively expressed) and Cox-2 (inducible isoform), which is achieved with classical NSAIDs, interferes with the housekeeping functions of Cox-1 and thereby causes serious side effects, such as peptic ulcer disease. Simultaneous inhibition of Cox-1 and Cox-2 hence is not a realistic approach for chemoprevention in individuals at low to moderate risk for cancer. On the other hand, it appears possible to avoid many NSAID-dependent side effects by selective inhibition of Cox-2, which is also the isoform that is upregulated in benign and malignant tumors. Through understanding the biochemistry of these enzymes and the regulation of Cox-1 and Cox-2 gene expression, we review how Cox-2 can be regulated selectively as a target for chemopreventive therapy. We also discuss the potential importance and advantages of a multifaceted approach to diminishing the function of Cox-2 (i.e., combining inhibitors of enzyme function with inhibitors of gene expression).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Surh, Y.-J., Chun, K.-S., Cha, H.-H., Han, S. S., Keum, Y.-S., Park, K.-K., & Lee, S. S. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00183-x · Cited by 1,620
Molecular basis for chemoprevention by sulforaphane: a comprehensive review
Juge, N., Mithen, R. F., & Traka, M. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6484-5 · Cited by 693
Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies
Tapiero, H., Nguyen Ba, G., Couvreur, P., & Tew, K. D. (2002) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(02)00193-2 · Cited by 635
Nuclear Factor κB Is a Molecular Target for Sulforaphane-mediated Anti-inflammatory Mechanisms
Heiss, E., Herhaus, C., Klimo, K., Bartsch, H., & Gerhäuser, C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104794200 · Cited by 632
Plummer, S. M., Holloway, K. A., Manson, M. M., Munks, R. J., Kaptein, A., Farrow, S., & Howells, L. (1999) · Oncogene · doi:10.1038/sj.onc.1202980 · Cited by 628
Possible Role of Ovarian Epithelial Inflammation in Ovarian Cancer
Ness, R. B., & Cottreau, C. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.17.1459 · Cited by 588
Chronic immune activation and inflammation as the cause of malignancy
O'Byrne, K. J., & Dalgleish, A. G. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1943 · Cited by 543
Many actions of cyclooxygenase‐2 in cellular dynamics and in cancer
Cao, Y., & Prescott, S. M. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10068 · Cited by 464
Hong, J. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh165 · Cited by 432
Mouse models for the study of colon carcinogenesis
Rosenberg, D. W., Giardina, C., & Tanaka, T. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn267 · Cited by 430
Baek, S. J., Kim, K.-S., Nixon, J. B., Wilson, L. C., & Eling, T. E. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)09260-5 · Cited by 401
Factors Related to Inflammation of the Ovarian Epithelium and Risk of Ovarian Cancer
Ness, R. B., Grisso, J. A., Cottreau, C., Klapper, J., Vergona, R., Wheeler, J. E., Morgan, M., & Schlesselman, J. J. (2000) · Epidemiology · doi:10.1097/00001648-200003000-00006 · Cited by 363
Buttar, N. S., Wang, K. K., Leontovich, O., Westcott, J. Y., Pacifico, R. J., Anderson, M. A., Krishnadath, K. K., Lutzke, L. S., & Burgart, L. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.32371 · Cited by 348
Selective inhibition of cyclooxygenase-2 by C-phycocyanin, a biliprotein from Spirulina platensis
Reddy, C. M., Bhat, V. B., Kiranmai, G., Reddy, M. N., Reddanna, P., & Madyastha, K. M. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3725 · Cited by 310
Dietary chalcones with chemopreventive and chemotherapeutic potential
Orlikova, B., Tasdemir, D., Golais, F., Dicato, M., & Diederich, M. (2011) · Genes & Nutrition · doi:10.1007/s12263-011-0210-5 · Cited by 273
Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells
Fukuda, K., Hibiya, Y., Mutoh, M., Koshiji, M., Akao, S., & Fujiwara, H. (1999) · Journal of Ethnopharmacology · doi:10.1016/s0378-8741(98)00162-7 · Cited by 270
Watkins, B. A., Li, Y., Allen, K. G. D., Hoffmann, W. E., & Seifert, M. F. (2000) · The Journal of Nutrition · doi:10.1093/jn/130.9.2274 · Cited by 269
Hong, J., Smith, T. J., Ho, C.-T., August, D. A., & Yang, C. S. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00767-5 · Cited by 261
Cyclooxygenase enzymes and prostaglandins in pathology of the endometrium
Sales, K. J., & Jabbour, H. N. (2003) · Reproduction · doi:10.1530/rep.0.1260559 · Cited by 177
“These findings have led to the observation that COX enzyme inhibitors may be of potential benefit as therapeutic regimens for uterine– cervical carcinomas, as has been suggested for other types of carcinoma highly expressing COX enzyme (Subbaramaiah et al., 1997).”
Background
Metadata
- Authors
- Subbaramaiah, K., Zakim, D., Weksler, B. B., & Dannenberg, A. J.
- Venue
- Experimental Biology and Medicine
- Publisher
- Frontiers Media SA
- Published
- 1997-11-01
- Volume
- 216
- Issue
- 2
- Pages
- 201-210
- ISSN
- 0071-3384 (ISSN-L)
- 1535-3702
- 1535-3699
- OpenAlex
- W2327667256
- Cited by
- 222
- References
- 0
- FWCI
- 11.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.